Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscription Services
Promote Your Event
Submission Forms
Place an Ad
Weather
News
Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Items For Sale
Jobs
Pets
Auctions, Estate & Garage Sales
Place an ad
Services
Community
Personals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BioNTech SE
BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
February 02, 2023
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
January 10, 2023
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
January 05, 2023
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 28, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
December 23, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China
December 22, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Update on First BioNTainer for African-based mRNA Manufacturing Facility
December 21, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
December 21, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
December 09, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
December 08, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
November 30, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
November 18, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
November 16, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore
November 13, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
November 10, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
November 07, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
November 04, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022
October 24, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
October 19, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
October 13, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
October 12, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility
October 06, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
July 27, 2022
From
BioNTech SE
Via
Globe NewsWire
Tickers
BNTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.